Albemarle Corporation (ALB)

Sector: Materials|Industry: Specialty Chemicals|Market Cap: $10.60B|Employees: 9K


Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

  1. Filings

Filing Highlights

Financial Performance

The 10-K reports net sales of $9.6 billion, a 31% increase compared to $7.3 billion in the prior year. This growth was attributed to higher sales volume in Energy Storage and Ketjen, and increased pricing primarily in Energy Storage.

The gross profit margin decreased to 12.3% compared to 42.0% in the prior year. This was due to higher costs from sales of lithium using higher-priced spodumene, and a $604.1 million charge to reduce the value of certain spodumene and finished goods inventory.

Selling, general, and administrative expenses increased by 75% year-over-year to $919.5 million, and research and development expenses increased by 19% to $85.7 million. These increases further reduced net income.

Growth & Strategy

Management Execution

Risk Factors

Competitive Position

Operational Efficiency

Innovation & Technology

Capital Allocation

ESG Initiatives

Market Environment